Pharmaceutical drug delivery market and systems
Pharmaceutical Technology
MARCH 22, 2024
Download our free, comprehensive list of the leading companies within the pharmaceutical drug delivery market.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Pharmaceutical Technology
MARCH 22, 2024
Download our free, comprehensive list of the leading companies within the pharmaceutical drug delivery market.
Bio Pharma Dive
AUGUST 8, 2023
The Indianapolis drugmaker is now worth more than $500 billion, higher than any other pharmaceutical company, as analysts project lucrative markets for its obesity and Alzheimer's drugs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
DECEMBER 3, 2020
Another TED talk on the evils of prescription drug marketing was filled with misinformation as usual. The disconnect between consumers and prescription drug marketing has grown quite a bit. What about marketing to doctors? The other issue is a payment to physicians.
World of DTC Marketing
AUGUST 10, 2022
CPG marketers are trying to maintain market share amid price increases and smaller product sizes, leading to a more significant jump in consumerism. But, in pharma marketing, the changes affect every product category. However, DTC marketing is different, much different. So what’s the opportunity for DTC marketers?
Pharmaceutical Technology
FEBRUARY 23, 2024
The FDA Office of Generic Drugs reported a rise in generic drug approvals, as several first-time generics entered the market.
Pharmaceutical Technology
OCTOBER 25, 2023
Experts discuss the key trends in quality improvements and API reshoring for the generic drugs market at CpHI Europe.
Pharmaceutical Technology
DECEMBER 5, 2023
Professor Timothy Mackey talks about the recent reports of fraudulent Ozempic pens and the challenges in chasing drug counterfeiters.
World of DTC Marketing
JULY 21, 2021
SUMMARY: DTC marketing is not the reason why prescription drugs cost so much. The voices in Washington DC are once again calling for a moratorium on DTC marketing but lawmakers need to understand what DTC marketing actually does as upped to what people believe it does. DTC ads raise awareness around health conditions.
Drug Discovery World
FEBRUARY 26, 2024
The global ADME toxicology testing market is predicted to generate a revenue of $19.21 Factors such as an increased need to check late-stage drug failures with the adoption of more appropriate toxicity testing methods by pharmaceutical companies are expected to aid revenue generation for the market.
Pharmaceutical Technology
JANUARY 23, 2023
As such, the SLE and LN marketplace is dominated by generics, and GSK’s Benlysta and AstraZeneca’s Saphnelo are the only drugs that have gained marketing approval specifically for SLE in more than 50 years. In previous years, Benlysta has managed to grow the lupus market in terms of value, having generated approximately $492.9m
Pharmaceutical Technology
SEPTEMBER 1, 2023
Novo Nordisk's obesity drugs are driving Danish growth as well as record profits as the company becomes second-most valuable in Europe.
Fierce Pharma
MARCH 8, 2024
After reporting the failu | After reporting the failure of a confirmatory trial of its amyotrophic lateral sclerosis drug Relyvrio (AMX0035), Amylyx Pharmaceuticals is uncertain whether it will pull the treatment from the market in the U.S. and in Canada, where it is known as Albrioza.
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 5, 2024
The Subject Expert Committee (SEC) which advises the national drug regulator on drug approvals and clinical trials has recommended grant of permission to drug major Astrazeneca for import and marketing of two strengths of anti-hyperkalaemia therapy drug Lokelma (sodium zirconium cyclosilicate for oral suspension).
Bio Pharma Dive
NOVEMBER 27, 2023
drugmaker withdrew the multiple myeloma drug from the U.S. market because of negative data, new study results might crack open the door to a relaunch. One year after the U.K.
Pharmaceutical Technology
JUNE 12, 2023
Lotus Pharmaceuticals and Teraju Pharma have entered a strategic partnership to market Lotus’s products in a range of therapeutic areas in Malaysia. Teraju Pharma will be responsible for marketing and promoting the products using its relationships and infrastructure.
Pharmaceutical Technology
MARCH 1, 2024
The top 20 biopharmaceutical companies saw prominent shifts in market capitalisation over 2023 despite various obstacles.
World of DTC Marketing
APRIL 20, 2022
We just finished talking to over 200 hundred HCPs about pharma marketing and salespeople to measure any differences since before the pandemic. This was especially true with new drugs that have a significant competitive market. Will they transform their HCP marketing or stick to dated models?
Pharmaceutical Technology
NOVEMBER 14, 2022
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Oncopeptides’ Pepaxti (melphalan flufenamide; melflufen) along with dexamethasone to treat multiple myeloma patients. Currently, the company is analysing Pepaxti’s market access options in the country.
Bio Pharma Dive
OCTOBER 6, 2022
The pharma will invest in the biotech and co-promote its drug teplizumab if the FDA OKs the medicine as a first-of-its-kind diabetes treatment.
World of DTC Marketing
JANUARY 12, 2022
The word influencer was added to the Merriam-Webster dictionary in 2019, but influencer marketing is nothing new. Scandals, fake followers, bot technologies, and the pandemic crisis converged have put a halt to influencer marketing growth and tarnished the public view of influencers as a whole. bilÂlion in 2021.
Drug Patent Watch
OCTOBER 2, 2023
The FDA conducted a study to identify factors that may predict the likelihood of generic drug marketing applications.
Drug Discovery World
FEBRUARY 20, 2024
The drug discovery informatics market is predicted to grow from $3.77 The new report says the anticipated growth to 2028 will be fuelled by the expansion of precision medicine, advancements in drug-drug interaction prediction, analysis of patient-derived data, development of biosimilars, and the increasing number of drug candidates.
Fierce Pharma
SEPTEMBER 7, 2023
Demand is so strong for Novo Nordisk’s obesity drugs that the only limitation on sales—in the short term—seems to be the company’s ability to produce them. Morgan, which has doubled its market projection for GLP-1 diabetes and obesity treatments to $71 billion for 2032.
Pharmaceutical Technology
JANUARY 2, 2024
The age-related macular degeneration (AMD) market is expected to grow at a compound annual growth rate of 14.1%
XTalks
OCTOBER 4, 2023
Health economics and outcomes research (HEOR) and market access strategies play a critical role in ensuring that newly approved therapies are made available to patients. Professionals in these roles are facing new challenges when it comes to negotiating coverage for many of the new, innovative treatments that are coming to market.
Drug Discovery World
JUNE 1, 2023
Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2.
Outsourcing Pharma
SEPTEMBER 29, 2023
Chinese biopharmaceutical company, Hutchmed Limited, has announced today (Friday September 29) that it has taken a step towards bringing a colon and rectum cancer drug to a third market.
Roots Analysis
FEBRUARY 27, 2024
Ambrx and NovoCodex Biopharmaceuticals announced that they have formed a second collaboration to develop and commercialize Ambrx’s internally developed site-specific antibody drug conjugates. The antibody drug conjugates market is expected to grow at a CAGR of ~10% during the forecast period.
pharmaphorum
JUNE 19, 2023
Weight-loss drugs ‘will be a $60bn market in 10 years’ Phil.Taylor Mon, 19/06/2023 - 10:21 Bookmark this
Medical Xpress
MARCH 16, 2023
An animal tranquilizer has flooded the illicit drug market in Maryland, according to a new study by the National Institute of Standards and Technology (NIST) and the Maryland Department of Health.
Fierce Pharma
MARCH 22, 2024
and China, Eli Lilly’s CEO said the Indianapolis-based company remains committed to the Chinese market. David Ricks’ visit to China comes as Lilly has several key drug applications under review at local regulators. At a time of heightened geopolitical tensions between the U.S.
pharmaphorum
JANUARY 11, 2024
Generative AI is revolutionising the pharmaceutical industry, accelerating the speed to market for new drugs. Learn how regulatory processes, R&D, and clinical trials are being impacted by this innovative technology.
Fierce Pharma
MARCH 27, 2024
For various reasons, pharma firms often favor distribution pacts rather than relying on local subsidiaries to market their drugs. |
ProRelix Research
NOVEMBER 2, 2023
Although clinical trials provide useful information regarding the efficacy and safety of new drugs, biological products, and medical devices, the information captured through them is not all-encompassing. Limited patient populations, […] The post Post-Marketing Surveillance Strategies appeared first on ProRelix Research.
Pharma Marketing Network
JULY 26, 2023
The Food and Drug Administration (FDA) plays a critical role in regulating the pharmaceutical industry and ensuring that medications and medical devices marketed to the public are safe, effective, and appropriately labeled.
Drug Patent Watch
MARCH 7, 2024
Annual Drug Patent Expirations for ULORIC Uloric is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are three… The post New patent expiration for Takeda Pharms drug ULORIC appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.
Fierce Pharma
JANUARY 13, 2023
AstraZeneca pulls leukemia drug Lumoxiti off market after disappointing sales. Fri, 01/13/2023 - 09:29.
Intouch Solutions
MARCH 19, 2024
They are more likely than men to suffer chronic conditions and use prescription drugs across all age groups. I believe there is hope; there are shiny specs of light that reflect optimism in women’s healthcare marketing today. Yes, you read that correctly, marketing. But marketers don’t need to abide by that.
Drug Discovery World
NOVEMBER 22, 2023
The European Commission (EC) has granted marketing authorisation for YORVIPATH (palopegteriparatide) as replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. YORVIPATH is Ascendis Pharma’s prodrug of parathyroid hormone (PTH 1-34), administered once daily.
STAT News
NOVEMBER 22, 2022
British pharma giant GSK said Tuesday that it will withdraw its blood cancer drug Blenrep from the U.S. market, following a request from the Food and Drug Administration. regulators are taking a more aggressive stance toward cancer drugs approved based on preliminary evidence of efficacy.
pharmaphorum
MAY 3, 2022
Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai. The class as a whole is, however, trying to break into a low-cost generic market, and almost inevitably is facing pushback from payers.
Drug Patent Watch
FEBRUARY 17, 2024
Annual Drug Patent Expirations for AURYXIA Auryxia is a drug marketed by Keryx Biopharms and is included in one NDA. There are fourteen patents… The post New patent expiration for Keryx Biopharms drug AURYXIA appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.
BioSpace
MARCH 8, 2021
Prescription drug watchdog GoodRx compiled a list of the 10 most expensive drugs on the market. The list includes drugs that can be acquired at the neighborhood pharmacy, as well as those only administered in a hospital setting.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content